The treatment of chronic hepatitis B: Focus on adefovir-like antivirals | Zendy

Hans L. Tillmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Author(s) -

Hans L. Tillmann

Publication year - 2008

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.s1965

Subject(s) - adefovir , lamivudine , entecavir , telbivudine , medicine , pegylated interferon , virology , chronic hepatitis , pharmacology , virus , ribavirin

SEVERAL OPTIONS FOR THE TREATMENT OF HEPATITIS B HAVE BEEN LICENSED IN THE LAST YEARS: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into "lamivudine-like" and "adefovir-like", which clinically differ in their capacity to induce "YMDD" mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research